Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ANDREW M SCHNEIDER

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1548276140
CMS profile
1260832
Location
TAMARAC, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$25.83

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $25.83 2

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
EISAI INC. $13.68 1
Janssen Biotech, Inc. $12.15 1

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ANDREW M SCHNEIDER

NPI 1548276140 · CMS profile ID 1260832

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

TAMARAC, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1548276140?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ANDREW M SCHNEIDER, NPI 1548276140, CMS profile ID 1260832. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1548276140?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). ANDREW M SCHNEIDER, NPI 1548276140, CMS profile ID 1260832. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1548276140?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
ANDREW M SCHNEIDER, NPI 1548276140, CMS profile ID 1260832, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1548276140?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $25.83 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
EISAI INC. $13.6811/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697019659 CMS
Janssen Biotech, Inc. $12.1505/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658696655 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $25.83 2
PY2021 $72.82 5
PY2022 $373.74 21
PY2023 $966.10 46
PY2024 $71.27 4

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2023, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $243,091.66 62
PY2024 Principal investigator $160,850.72 38

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

62 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $120.00 12/19/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184278938
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $75.00 12/19/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184278940
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $103.50 12/19/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184278942
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $138.00 12/19/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184278944
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,569.56 12/19/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184278946
Principal investigator 1 PFIZER INC. $38,400.00 12/18/2025 Non-covered Recipient Entity
BRCR Medical Center Inc
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228744115
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $69.96 12/17/2025 Non-covered Recipient Entity
Brcr Global-Florida
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220996242
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,756.90 12/11/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184274570
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $650.00 12/09/2025 Non-covered Recipient Entity
BRCR Medical Center INC
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220813043
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,323.41 12/04/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184269149
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,300.00 11/12/2025 Non-covered Recipient Entity
BRCR Medical Center INC
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220813041
Principal investigator 1 Daiichi Sankyo Inc. $51.75 11/03/2025 Non-covered Recipient Entity
BRCR Global
DS1062-328 No dispute reported 06/30/2026 1223364979
Principal investigator 1 Daiichi Sankyo Inc. $94.00 11/03/2025 Non-covered Recipient Entity
BRCR Global
DS1062-328 No dispute reported 06/30/2026 1223364981
Principal investigator 1 Daiichi Sankyo Inc. $376.00 11/03/2025 Non-covered Recipient Entity
BRCR Global
DS1062-328 No dispute reported 06/30/2026 1223364983
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,300.00 10/21/2025 Non-covered Recipient Entity
BRCR Medical Center INC
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220813033
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,300.00 10/21/2025 Non-covered Recipient Entity
BRCR Medical Center INC
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220813035
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,300.00 10/21/2025 Non-covered Recipient Entity
BRCR Medical Center INC
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220813037
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,300.00 10/21/2025 Non-covered Recipient Entity
BRCR Medical Center INC
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220813039
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $750.00 10/17/2025 Non-covered Recipient Entity
BRCR Medical Center INC
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220813031
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,300.00 10/16/2025 Non-covered Recipient Entity
BRCR Medical Center INC
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220813029
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,300.00 09/15/2025 Non-covered Recipient Entity
BRCR Medical Center INC
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220813027
Principal investigator 1 Daiichi Sankyo Inc. $3,800.00 09/03/2025 Non-covered Recipient Entity
BRCR Global
DS1062-328 No dispute reported 06/30/2026 1223364965
Principal investigator 1 Daiichi Sankyo Inc. $7,000.00 09/03/2025 Non-covered Recipient Entity
BRCR Global
DS1062-328 No dispute reported 06/30/2026 1223364967
Principal investigator 1 Daiichi Sankyo Inc. $30,000.00 09/03/2025 Non-covered Recipient Entity
BRCR Global
DS1062-328 No dispute reported 06/30/2026 1223364969
Principal investigator 1 Daiichi Sankyo Inc. $2,500.00 09/03/2025 Non-covered Recipient Entity
BRCR Global
DS1062-328 No dispute reported 06/30/2026 1223364971
Principal investigator 1 Daiichi Sankyo Inc. $4,900.00 09/03/2025 Non-covered Recipient Entity
BRCR Global
DS1062-328 No dispute reported 06/30/2026 1223364973
Principal investigator 1 Daiichi Sankyo Inc. $2,000.00 09/03/2025 Non-covered Recipient Entity
BRCR Global
DS1062-328 No dispute reported 06/30/2026 1223364975
Principal investigator 1 Daiichi Sankyo Inc. $2,500.00 09/03/2025 Non-covered Recipient Entity
BRCR Global
DS1062-328 No dispute reported 06/30/2026 1223364977
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $750.00 08/27/2025 Non-covered Recipient Entity
BRCR Medical Center INC
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220813025
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $67.88 08/26/2025 Non-covered Recipient Entity
Brcr Global-Florida
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220996238
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $46.64 08/26/2025 Non-covered Recipient Entity
Brcr Global-Florida
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220996240
Principal investigator 1 Daiichi Sankyo Inc. $44.70 08/25/2025 Non-covered Recipient Entity
BRCR Global
DS3201-324 No dispute reported 06/30/2026 1223364861
Principal investigator 1 Daiichi Sankyo Inc. $74.50 08/25/2025 Non-covered Recipient Entity
BRCR Global
DS3201-324 No dispute reported 06/30/2026 1223364863
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,300.00 08/21/2025 Non-covered Recipient Entity
BRCR Medical Center INC
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220813023
Principal investigator 1 Celgene Corporation $10,300.00 07/23/2025 Non-covered Recipient Entity
Brcr Global
A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1222305776
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,323.41 06/05/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184204145
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,021.84 06/05/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184204147
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,394.28 06/05/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184204149
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $750.00 05/13/2025 Non-covered Recipient Entity
BRCR Medical Center INC
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220813021
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $26,467.95 05/12/2025 Non-covered Recipient Entity
BRCR Medical Center INC
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220813019
Principal investigator 1 Daiichi Sankyo Inc. $750.00 05/09/2025 Non-covered Recipient Entity
BRCR Global
DS3201-324 No dispute reported 06/30/2026 1223364999
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $356.37 03/25/2025 Non-covered Recipient Entity
Brcr Global-Florida
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220996226
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $291.50 03/25/2025 Non-covered Recipient Entity
Brcr Global-Florida
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220996228
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $119.88 03/25/2025 Non-covered Recipient Entity
Brcr Global-Florida
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220996230
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $73.00 03/25/2025 Non-covered Recipient Entity
Brcr Global-Florida
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220996232
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $16.80 03/25/2025 Non-covered Recipient Entity
Brcr Global-Florida
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220996234
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $16.50 03/25/2025 Non-covered Recipient Entity
Brcr Global-Florida
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220996236
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $22,847.50 03/18/2025 Non-covered Recipient Entity
BRCR Medical Center INC
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220813017
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,424.40 03/10/2025 Non-covered Recipient Entity
BRCR Medical Center INC
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220813013
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,765.00 03/10/2025 Non-covered Recipient Entity
BRCR Medical Center INC
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220813015
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,841.00 03/07/2025 Non-covered Recipient Entity
BRCR Medical Center INC
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220813011
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $33.94 02/25/2025 Non-covered Recipient Entity
Brcr Global-Florida
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220996220
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $104.94 02/25/2025 Non-covered Recipient Entity
Brcr Global-Florida
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220996222
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $4.50 02/25/2025 Non-covered Recipient Entity
Brcr Global-Florida
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220996224
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,765.00 02/21/2025 Non-covered Recipient Entity
BRCR Medical Center INC
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220813009
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $650.00 02/14/2025 Non-covered Recipient Entity
BRCR Medical Center INC
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220813003
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,765.00 02/05/2025 Non-covered Recipient Entity
BRCR Medical Center INC
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220813007
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,033.00 02/01/2025 Non-covered Recipient Entity
BRCR Medical Center INC
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220812999
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,147.00 02/01/2025 Non-covered Recipient Entity
BRCR Medical Center INC
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220813001
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $650.00 01/13/2025 Non-covered Recipient Entity
BRCR Medical Center INC
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220813005
Principal investigator 1 Daiichi Sankyo Inc. $50.00 01/10/2025 Non-covered Recipient Entity
BRCR Global
DS3201-324 No dispute reported 06/30/2026 1223364865
Principal investigator 1 Daiichi Sankyo Inc. $567.05 01/10/2025 Non-covered Recipient Entity
BRCR Global
DS3201-324 No dispute reported 06/30/2026 1223364867